SAGE Therapeutics Inc (SAGE) – Debunking Asclepia Capital’s “Scientific Response” by Kerrisdale Capital Disclosure We are short shares of SAGE Therapeutics Inc. Please click here to read full disclosures. In the wake of our report on Sage Therapeutics, Asclepia Capital, a biotech-focused hedge fund, released a seven-page response purporting to “debunk” what it characterized as our “superficial analysis.” While we always appreciate substantive criticism, we disagree with all of Asclepia’s key points, which we address one by one below. It’s also worth noting what Asclepia does not discuss. It offers no explanation for why SAGE-547 would outperform placebo in Phase…
This content is exclusively for paying members of Hedge Fund Alpha
Insider Strategies and Letters to Shareholders from the Top Hedge Funds and Maximize Your Portfolio Growth with Hedge Fund Alpha
Don’t have an account?
Subscribe now and get 7 days free!
